Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial

Authors: Falk Roeder, Burkhard Lehner, Thomas Schmitt, Bernd Kasper, Gerlinde Egerer, Oliver Sedlaczek, Carsten Grüllich, Gunhild Mechtersheimer, Patrick Wuchter, Frank W Hensley, Peter E Huber, Juergen Debus, Marc Bischof

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

To report the results of a subgroup analysis of a prospective phase II trial focussing on radiation therapy and outcome in patients with extremity soft tissue sarcomas (STS).

Methods

Between 2005 and 2010, 50 patients (pts) with high risk STS (size ≥ 5 cm, deep/extracompartimental location, grade II-III (FNCLCC)) were enrolled. The protocol comprised 4 cycles of neoadjuvant chemotherapy with EIA (etoposide, ifosfamide and doxorubicin), definitive surgery with IOERT, postoperative EBRT and 4 adjuvant cycles of EIA. 34 pts, who suffered from extremity tumors and received radiation therapy after limb-sparing surgery, formed the basis of this subgroup analysis.

Results

Median follow-up from inclusion was 48 months in survivors. Margin status was R0 in 30 pts (88%) and R1 in 4 pts (12%). IOERT was performed as planned in 31 pts (91%) with a median dose of 15 Gy, a median electron energy of 6 MeV and a median cone size of 9 cm. All patients received postoperative EBRT with a median dose of 46 Gy after IOERT or 60 Gy without IOERT. Median time from surgery to EBRT and median EBRT duration was 36 days, respectively. One patient developed a local recurrence while 11 patients showed nodal or distant failures. The estimated 5-year rates of local control, distant control and overall survival were 97%, 66% and 79%, respectively. Postoperative wound complications were found in 7 pts (20%), resulting in delayed EBRT (>60 day interval) in 3 pts. Acute radiation toxicity mainly consisted of radiation dermatitis (grade II: 24%, no grade III reactions). 4 pts developed grade I/II radiation recall dermatitis during adjuvant chemotherapy, which resolved during the following cycles. Severe late toxicity was observed in 6 pts (18%). Long-term limb preservation was achieved in 32 pts (94%) with good functional outcome in 81%.

Conclusion

Multimodal therapy including IOERT and postoperative EBRT resulted in excellent local control and good overall survival in patients with high risk STS of the extremities with acceptable acute and late radiation side effects. Limb preservation with good functional outcome was achieved in the majority of patients.

Trial registration

ClinicalTrials.gov NCT01382030, EudraCT 2004-002501-72, 17.​06.​2011
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics 2009. CA Cancer J Clin. 2009, 59: 225-249. 10.3322/caac.20006.CrossRefPubMed
2.
Jebsen NL, Trovik CS, Bauer HC, Rydholm A, Monge OR, Sundby Hall K, Alvegard T, Bruland OS: Radiotherapy to improve local control regardless of surgical margin and malignancy grade in extremity and trunk wall soft tissue sarcoma: a Scandinavian sarcoma group study. Int J Radiat Oncol Biol Phys. 2008, 71: 1196-1203. 10.1016/j.ijrobp.2007.11.023.CrossRefPubMed
3.
Pisters WT, Leung DH, Woodruff J, Shi W, Brennan F: Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996, 14: 1679-1689.PubMed
4.
Trovik CS, Bauer HC, Alvegaard TA, Anderson H, Blomqvist C, Berlin O, Gustafson P, Saeter G, Walloe A: Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian sarcoma group register. Eur J Cancer. 2000, 36: 710-716. 10.1016/S0959-8049(99)00287-7.CrossRefPubMed
5.
Stefanovski PD, Bidole E, De Paoli A, Buonadonna A, Boz G, Libra M, Morassut S, Rossi C, Carbone A, Frustraci S: Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol. 2003, 28: 153-164.CrossRef
6.
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL: Prognostic factors for patients with localized soft-tissue sarcomas treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003, 97: 2530-2543. 10.1002/cncr.11365.CrossRefPubMed
7.
Schmitt T, Lehner B, Kasper B, Bischof M, Roeder F, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Mechtersheimer G, Wuchter P, Ho AD, Egerer G: A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcomas. BMC Cancer. 2011, 11: 510-10.1186/1471-2407-11-510.CrossRefPubMedPubMedCentral
8.
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, Lehner B, Haberkorn U, Stroebel P, Kasper B: Impact of dynamic 18-F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med. 2010, 51: 551-558. 10.2967/jnumed.109.070862.CrossRefPubMed
9.
Lewis JJ, Leung D, Woodruff JM, Brennan MF: Retroperitoneal soft-tissue sarcoma – analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998, 228: 355-365. 10.1097/00000658-199809000-00008.CrossRefPubMedPubMedCentral
10.
Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PT: Retroperitoneal Soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007, 67: 158-163. 10.1016/j.ijrobp.2006.08.025.CrossRefPubMed
11.
Salzer-Kuntschik M, Delling G, Beron G, Sigmund R: Morphological grades of regression in osteosarcoma after polychemotherapy – study COSS 80. J Cancer Res Clin Oncol. 1983, 106 (suppl): 21-24.CrossRefPubMed
12.
Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R: The treatment of soft-tissue sarcomas of the extremities. Ann Surg. 1982, 196: 305-314. 10.1097/00000658-198209000-00009.CrossRefPubMedPubMedCentral
13.
Edmonson JH, Petersen IA, Shives TC, Mahoney MR, Rock MG, Haddock MG, Sim FH, Maples WJ, O‘Connor MI, Gundersson LL, Foo ML, Pritchard DJ, Buckner JC, Stafford SL: Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft-tissue sarcomas. Cancer. 2002, 94: 786-792. 10.1002/cncr.10259.CrossRefPubMed
14.
Azinovic I, Martinez Monge R, Javier Aristu J, Salgado E, Villafranca E, Fernandez Hidalgo O, Amillo S, San Julian M, Villas C, Manuel Aramendia J, Calvo FA: Intraoperative radiotherapy electron boost followed by moderate doses of external beam radiotherapy in resected soft-tissue sarcomas of the extremities. Radiother Oncol. 2003, 67: 331-337. 10.1016/S0167-8140(03)00163-4.CrossRefPubMed
15.
Kretzler A, Molls M, Gradinger R, Lukas P, Steinau HU, Würschmidt F: Intraoperative radiotherapy of soft tissue sarcomas of the extremity. Strahlenther Onkol. 2004, 180: 365-370. 10.1007/s00066-004-1191-8.CrossRefPubMed
16.
Oertel S, Treiber M, Zahlten-Hinguranage A, Eichin S, Roeder F, Funk A, Hensley FW, Timke C, Niethammer AG, Huber PE, Weitz J, Eble MJ, Buchler MW, Bernd L, Debus J, Krempien R: Intraoperative electron boost radiation followed by moderate doses of external beam radiotherapy in limb-sparing treatment of patients with extremity soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 2006, 64: 1416-1423. 10.1016/j.ijrobp.2005.10.009.CrossRefPubMed
17.
Llacer C, Delannes M, Minsat M, Stoeckle E, Votron L, Martel P, Bonnevialle P, Bui BG, Chevreau C, Kantor G, Daly-Schveitzer N, Thomas L: Low-dose intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structure. Radiother Oncol. 2006, 78: 10-16. 10.1016/j.radonc.2005.12.002.CrossRefPubMed
18.
Alvarez A, Calvo FA, Gonzales C, Ferrer M, Lozano MA, Calin A, Casteleiro R, Alvarez E, Pedrero F, Herranz R: IORT in soft tissue sarcomas involving extremities: toxicities and long-term functional results [abstract]. Revisiones en Cancer. 2008, 22: s55-
19.
Hui AC, Ngan SY, Wong K, Powell G, Choong PF: Preoperative radiotherapy for soft tissue sarcoma: the Peter MacCallum Cancer Centre Experience. Eur J Surg Oncol. 2006, 32: 1159-1164. 10.1016/j.ejso.2006.04.003.CrossRefPubMed
20.
Dagan R, Indelicato DJ, McGee L, Morris CG, Kirwan JM, Knapik J, Reith J, Scarborough MT, Gibbs CP, Marcus RB, Zlotecki RA: The significance of a marginal excision after preoperative radiation therapy of soft tissue sarcoma of the extremity. Cancer. 2012, 118: 3199-3207. 10.1002/cncr.26489.CrossRefPubMed
21.
MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag A, Undevia SD, Connell PP: Primary tumor necrosis predicts distant control in locally advanced soft tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010, 76: 1147-1153. 10.1016/j.ijrobp.2009.03.015.CrossRefPubMed
22.
Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson D, Eisenberg B: Phase II Study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: radiation therapy oncology group trial 9514. J Clin Oncol. 2006, 24: 619-625. 10.1200/JCO.2005.02.5577.CrossRefPubMed
23.
Felderhof JM, Creutzberg CL, Putter H, Nout RA, Bovee JM, Dijkstra PD, Hartgrink HH, Marijnen CA: Long term clinical outcome of patients with soft-tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy. Acta Oncol. 2012, 52: 745-752.CrossRefPubMed
24.
Alektiar KM, Brennan MF, Singer S: Local Control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer. 2011, 117: 3229-3234. 10.1002/cncr.25882.CrossRefPubMed
25.
Lee J, Park YJ, Yang DS, Yoon WS, Lee JA, Rim CH, Kim CY: Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma. Radiat Oncol J. 2012, 30: 62-69. 10.3857/roj.2012.30.2.62.CrossRefPubMedPubMedCentral
26.
Sampath S, Schultheiss TE, Hitchcock YJ, Randall RL, Shrieve DC, Wong JY: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma: multi-institutional analysis of 821 patients. Int J Radiat Oncol Biol Phys. 2011, 81: 498-505. 10.1016/j.ijrobp.2010.06.034.CrossRefPubMed
27.
O‘Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomized trial. Lancet. 2002, 359: 2235-2241. 10.1016/S0140-6736(02)09292-9.CrossRefPubMed
28.
O‘Sullivan B, Davis AM, Turcotte R, Bell R, Wunder J, Catton C, Kandel R, Sadura A, Tu D, Pater J: Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft-tissue sarcoma [abstract]. J Clin Oncol. 2004, 22: s819-
29.
Davis AM, O‘Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, Wunde J, Hammond A, Benk V, Kandel R, Goddard K, Freeman C, Sadura A, Zee B, Day A, Tu D, Pater J: Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005, 75: 48-53. 10.1016/j.radonc.2004.12.020.CrossRefPubMed
30.
Stinson SF, DeLaney TF, Greenberg J, Yang JC, Lampert MH, Hicks JE, Venzon D, White DE, Rosenberg SA, Glatstein EJ: Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1991, 21: 1493-1499. 10.1016/0360-3016(91)90324-W.CrossRefPubMed
31.
Alektiar KM, Hong L, Brennan MF, Della-Biancia C, Singer S: Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys. 2007, 68: 458-464. 10.1016/j.ijrobp.2006.12.054.CrossRefPubMed
32.
33.
Kodym E, Kalinska R, Ehringfeld C, Sterbik-Lamina A, Kodym R, Hohenberg G: Frequency of radiation recall dermatitis in adult cancer patients. Onkologie. 2005, 28: 18-21.CrossRefPubMed
34.
Haffty BG, Vicini FA, Beitsch P, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Zannis V, Kuerer H, Whitacre E, Whitworth P, Fine R, Keisch M: Timing of chemotherapy after mammosite radiation therapy system breast brachytherapy: analysis of the American society of breast surgeons mammosite breast brachytherapy registry trial. Int J Radiat Oncol Biol Phys. 2008, 72: 1441-1448. 10.1016/j.ijrobp.2008.02.070.CrossRefPubMed
35.
Camidge R, Price A: Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001, 59: 237-245. 10.1016/S0167-8140(01)00328-0.CrossRefPubMed
36.
van Kampen M, Eble MJ, Lehnert T, Bernd L, Jensen K, Hensley F, Krempien R, Wannenmacher M: Correlation of intraoperatively irradiated volume and fibrosis in patients with soft-tissue sarcoma of the extremities. Int J Radiat Oncol Biol Phys. 2001, 51: 94-99.CrossRefPubMed
37.
Sindelar WF, Kinsella TJ: Normal tissue tolerance to intraoperative radiotherapy. Surg Oncol Clin N Am. 2003, 12: 925-942. 10.1016/S1055-3207(03)00087-5.CrossRefPubMed
38.
Kunos C, Colussi V, Getty P, Kinsella T: Intraoperative Electron Radiotherapy for Extremity Sarcomas does not increase acute or late morbidity. Clin Orthop Rel Res. 2005, 446: 247-252.CrossRef
39.
Cannon CP, Ballo MT, Zagars GK, Mirza AN, Lin PP, Lewis VO, Yasko AW, Benjamin RS, Pisters PW: Complications of combined modality treatment of primary lower extremity soft-tissue sarcomas. Cancer. 2006, 107: 2455-2461. 10.1002/cncr.22298.CrossRefPubMed
40.
Gortzak Y, Lockwood GA, Mahendra A, Wang Y, Chung PW, Catton CN, O‘Sullivan B, Deheshi BM, Wunder JS, Ferguson PC: Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer. 2010, 116: 1553-1559. 10.1002/cncr.24949.CrossRefPubMed
41.
Rimner A, Brennan MF, Zhang Z, Singer S, Alektiar KM: Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer. 2009, 115: 149-157. 10.1002/cncr.23975.CrossRefPubMed
42.
Bramwell V, Rouesse J, Steward W, Santoro A, Schraffordt-Koops H, Buesa J, Ruka W, Priario J, Wagener T, Burgers M, van Unnik J, Contesso G, Thomas D, van Glabekke M, Markham D, Pinedo H: Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma – reduced local recurrence but no improvement in survival: a study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol. 1994, 12: 1137-1149.PubMed
43.
Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P: Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenogastrim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012, 13: 1045-1054. 10.1016/S1470-2045(12)70346-7.CrossRefPubMed
44.
Frustraci S, Gherlinzoni F, de Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the italian randomized cooperative trial. J Clin Oncol. 2001, 19: 1238-1247.
45.
Petrioli R, Coratti A, Correale R, D‘Aniello C, Grimaldi L, Tanzini G, Civitelli S, Marsili S, Messinese S, Marzocca G, Pirtoli L, Francini G: Adjuvant epirubicin with or without ifosfamid for adult soft tissue sarcoma. Am J Clin Oncol. 2002, 25: 468-473. 10.1097/00000421-200210000-00009.CrossRefPubMed
46.
Sarcoma Meta-analysis collaboration (SMAC): Adjuvant chemotherapy for localised resectable soft tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997, 350: 1647-1654.CrossRef
47.
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft- tissue sarcoma. Cancer. 2008, 113: 573-581. 10.1002/cncr.23592.CrossRefPubMed
48.
Eilber FC, Rosen G, Eckhardt J, Forscher C, Nelson SD, Selch M, Dorey F, Eilber FR: Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extermity soft tissue sarcomas. J Clin Oncol. 2001, 19: 3203-3209.PubMed
49.
Schuetze S, Patel S: Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?. Oncologist. 2009, 14: 1003-1012. 10.1634/theoncologist.2009-0007.CrossRefPubMed
50.
Delaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC: Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003, 56: 1117-1127. 10.1016/S0360-3016(03)00186-X.CrossRefPubMed
51.
Mullen JT, Kobayashi W, Wang JJ, Harmon DC, Choy E, Hornicek FJ, Rosenberg AE, Chen YL, Spiro IJ, DeLaney TF: Long–term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large extremity soft tissue sarcomas. Cancer. 2012, 118: 3758-3765. 10.1002/cncr.26696.CrossRefPubMed
52.
Gortzak E, Azzarelli A, Buesa J, Bramwell VC, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J: A randomised phase II study on neoadjuvant chemotherapy for high-risk adult soft-tissue sarcoma. Eur J Cancer. 2001, 37: 1096-1103. 10.1016/S0959-8049(01)00083-1.CrossRefPubMed
53.
Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P: Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010, 11: 561-570. 10.1016/S1470-2045(10)70071-1.CrossRefPubMedPubMedCentral
Metadata
Title
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial
Authors
Falk Roeder
Burkhard Lehner
Thomas Schmitt
Bernd Kasper
Gerlinde Egerer
Oliver Sedlaczek
Carsten Grüllich
Gunhild Mechtersheimer
Patrick Wuchter
Frank W Hensley
Peter E Huber
Juergen Debus
Marc Bischof
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-350

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Clinical and prognostic significance of preoperative plasma hyperfibrinogenemia in gallbladder cancer patients following surgical resection: a retrospective and in vitro study

Research article

Cytosolic galectin-7 impairs p53 functions and induces chemoresistance in breast cancer cells

Research article

Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men

Research article

Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS

Hypothesis

Epistemology of the origin of cancer: a new paradigm

Research article

GGPPS1 predicts the biological character of hepatocellular carcinoma in patients with cirrhosis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits